Celldex posts investor presentation highlighting barzolvolimab late-stage chronic urticaria program milestonesPUBT·Aug 14 at 04:04 PMCLDX-4.94%
Biotech Stocks At 52-Week Highs - SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSXrttnews·Aug 11 at 03:09 AMSLN-3.67%CLDX-4.94%
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High - Time to Buy?Market Beat·Aug 11 at 02:20 AMCLDX-4.94%
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 millionPUBT·Aug 6 at 03:08 PMCLDX-4.94%
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceMarket Beat·Jul 29 at 11:18 AMCLDX-4.94%UBS+0.23%
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% RunSimplywall·Jul 22 at 04:12 PMCLDX-4.94%
Wells Fargo & Company Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceMarket Beat·Jul 22 at 02:18 PMCLDX-4.94%WFC-2.32%
Cantor Fitzgerald Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock PriceMarket Beat·Jul 22 at 08:12 AMCLDX-4.94%
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Studybenzinga_article·Jul 22 at 06:29 AMCLDX-4.94%
